Talphera (TLPH) Return on Sales (2011 - 2025)

Talphera (TLPH) posted quarterly Return on Sales of 0.03% for Q4 2025, little changed quarter-over-quarter from 0.03% in Q3 2025.

Talphera (TLPH) Return on Sales (2011 - 2025) Analysis & Trends

Talphera's Return on Sales history runs 15 years deep, the most recent figure standing at 0.03% for Q4 2025.

In Q4 2025, Return on Sales changed N/A year-over-year to 0.03%; the TTM figure through Dec 2025 stood at 0.03% (changed N/A YoY), while the FY2025 annual figure was 0.03%, changed N/A from the prior year.
Return on Sales for Q4 2025 stood at 0.03%, roughly flat from 0.03% in the prior quarter.
The five-year high for Return on Sales was 0.16% in Q1 2023, with the low at 2.71% in Q4 2021.
The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.19%.
The sharpest annual moves came in 2021 and 2022: Return on Sales slumped 259 bps in 2021, then surged 245 bps in 2022.
Talphera's Return on Sales stood at 2.71% in 2021, then soared by 91 bps to 0.26% in 2022, then jumped by 100 bps to 0.0% in 2023, then changed by 0 bps to 0.0% in 2024, then soared by 6205 bps to 0.03% in 2025.
Business Quant data shows TLPH's Return on Sales at 0.03% in Q4 2025, 0.03% in Q3 2025, and 0.03% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	0.00%
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn	0.00%
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Talphera	90.35 Mn	90.35 Mn	-	-141.22%

Download Data